Your shopping cart is currently empty

BRM/BRG1 ATP-IN-7 (Compound Cpd69) functions as a selective dual inhibitor, effectively targeting BRM (SMARCA2) and BRG1 (SMARCA4) with IC50 values of 12 nM and 8 nM, respectively. It shows potential for research in BRM/BRG1-dependent cancers, such as non-small cell lung cancer and Ewing's sarcoma, as well as virus-associated diseases like HPV infection.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | BRM/BRG1 ATP-IN-7 (Compound Cpd69) functions as a selective dual inhibitor, effectively targeting BRM (SMARCA2) and BRG1 (SMARCA4) with IC50 values of 12 nM and 8 nM, respectively. It shows potential for research in BRM/BRG1-dependent cancers, such as non-small cell lung cancer and Ewing's sarcoma, as well as virus-associated diseases like HPV infection. |
| Molecular Weight | 511.57 |
| Formula | C23H21N5O5S2 |
| Cas No. | 2468048-19-1 |
| Smiles | N(C([C@@H](NC(=O)C1=CN(S(C)(=O)=O)C=C1)CO)=O)C2=NC(=CS2)C3=CC(=CC=C3)C=4C=CN=CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.